Boehringer Ingelheim obtains EMA authorization for Reprocyc^® ParvoFLEX, a new porcine parvovirus vaccine

Ingelheim, Germany, 1 October 2019 – After obtaining the marketing authorization from the European Commission^{1, 2} Boehringer Ingelheim launches Reprocyc^® ParvoFLEX in selected countries within the EU, a new porcine parvovirus vaccine to protect swine fetuses against transplacental infection caused by porcine parvovirus (PPV). 

PPV is a reproductive disease present in most of the pig farms worldwide. It causes fetal death, particularly mummification of fetuses, and is associated with other reproductive disorders. Many vaccines against PPV are available in the market; however, Reprocyc^® ParvoFLEX is a subunit vaccine based on a more recent isolate from 2001 (strain 27a) that uses a manufacturing technology of baculovirus expression system (also used with Ingelvac CircoFLEX^®) to express one region of the virus (VP2 region) where most of the immune response is targeted3.

Reprocyc^® ParvoFLEX can be mixed and administered with Reprocyc^® PRRS EU, a vaccine for active immunization of breeding females affected with European (genotype 1) Porcine Reproductive and Respiratory Syndrome (PRRS); it approved for use at any stage of gestation and lactation, so it can be introduced to the current PRRS control programs of sow herds.

PRRS continues to be a highly prevalent disease³ in pig farms causing economic losses through its negative effects on reproduction and growth as well as by clinical illness.

Martin Forchieri, Marketing Head of Swine Strategic Business Unit at Boehringer Ingelheim, shared: “I am really proud we continuously bring innovation to the market and keep addressing our customers’ needs.” This sentiment echoed by Xavier de Paz Solanes, Global Brand Manager at Boehringer Ingelheim, who added: “With this new product, veterinarians and producers can simultaneously control two of the most prevalent reproductive diseases in swine herds.”

Boehringer Ingelheim Animal Health Business Unit

Boehringer Ingelheim is the second largest animal health business in the world, with net sales of almost 4 billion euros in 2018 and presence in more than 150 markets.

Across the globe, our 10,000 employees create the future of animal wellbeing through their daily work. We believe in prevention over treatment and therefore, we focus on developing innovative solutions in the field of vaccines, parasiticides and therapeutics. With a large portfolio of advanced, preventive healthcare products, tools and services, we support our customers in taking care of the health of their animals.

For more information visit: www.boehringer-ingelheim.com/animal-health/overview.

Boehringer Ingelheim

Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around 17.5 billion euros. R&D expenditure of almost 3.2 billion euros, corresponded to 18.1 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: https://annualreport.boehringer-ingelheim.com.

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

References

¹https://ec.europa.eu/health/documents/community-register/2019/20190426144238/dec_144238_en.pdf

²https://www.ema.europa.eu/en/documents/smop-initial/cvmp-summary-positive-opinion-reprocyc-parvoflex_en.pdf

³Production and purification of VP2 protein of porcine parvovirus expressed in an insectbaculovirus cell system Zhou et al. Virology Journal 2010, 7:366